GERON CORP Increase (Decrease) in Prepaid Expense
GERON CORP (GERN) reported Increase (Decrease) in Prepaid Expense of -$443.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-03-02
- GERON CORP increase (decrease) in prepaid expense for fiscal 2025 was -$443.00K, a 353.14% decline from fiscal 2024.
- GERON CORP increase (decrease) in prepaid expense for fiscal 2024 was $175.00K, a 80.25% decline from fiscal 2023.
- GERON CORP increase (decrease) in prepaid expense for fiscal 2023 was $886.00K, a 66.31% decline from fiscal 2022.
- GERON CORP increase (decrease) in prepaid expense for fiscal 2022 was $2.63M.
| Period end | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|
| 2025-12-31 | -$443.00K 10-K · filed 2026-03-02 |
| 2024-12-31 | $175.00K 10-K · filed 2026-03-02 |
| 2023-12-31 | $886.00K 10-K · filed 2026-03-02 |
| 2022-12-31 | $2.63M 10-K · filed 2025-02-27 |
| 2021-12-31 | -$1.32M 10-K · filed 2024-02-28 |
| 2020-12-31 | $1.29M 10-K · filed 2023-03-16 |
| 2019-12-31 | -$121.00K 10-K · filed 2022-03-10 |
| 2018-12-31 | $752.00K 10-K · filed 2021-03-11 |
| 2017-12-31 | $56.00K 10-K · filed 2020-03-12 |
| 2016-12-31 | -$123.00K 10-K · filed 2019-03-07 |
| 2015-12-31 | -$89.00K 10-K · filed 2018-03-16 |
| 2014-12-31 | $72.00K 10-K · filed 2017-03-01 |
| 2013-12-31 | -$1.08M 10-K · filed 2016-03-10 |
| 2012-12-31 | -$1.31M 10-K · filed 2015-03-11 |
| 2011-12-31 | -$4.08M 10-K · filed 2014-03-17 |
| 2010-12-31 | -$2.87M 10-K · filed 2013-03-15 |
| 2009-12-31 | -$3.02M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |